| Nov 14 |
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
|
| Nov 14 |
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
|
| Nov 13 |
Syros cut to neutral by H.C. Wainwright on failed drug study
|
| Nov 13 |
Syros stock craters after lead cancer therapy flops in Phase III trial
|
| Nov 13 |
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
|
| Nov 12 |
Syros stock dives 92% on failed Phase 3 study, possible loan default (update)
|
| Nov 12 |
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
|
| Nov 2 |
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)
|
| Nov 1 |
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...
|
| Oct 31 |
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
|
